HLscience Valuation

Is A239610 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A239610 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A239610's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A239610's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A239610?

Key metric: As A239610 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A239610. This is calculated by dividing A239610's market cap by their current revenue.
What is A239610's PS Ratio?
PS Ratio	3x
Sales	₩22.05b
Market Cap	₩67.07b

A239610 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.8x
Enterprise Value/EBITDA	-9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A239610's PS Ratio compare to its peers?

The above table shows the PS ratio for A239610 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.2x
A270870 Newtree	0.4x	n/a	₩54.2b
A065170 BL Pharmtech	1.1x	n/a	₩18.4b
A318010 Pharmsville	1.9x	n/a	₩35.8b
A175250 Icure Pharmaceutical Incorporation	1.2x	n/a	₩74.6b
A239610 HLscience	3x	n/a	₩67.1b

Price-To-Sales vs Peers: A239610 is expensive based on its Price-To-Sales Ratio (3x) compared to the peer average (1.2x).

Price to Sales Ratio vs Industry

How does A239610's PS Ratio compare vs other companies in the KR Personal Products Industry?

1 Company	Price / Sales	Estimated Growth	Market Cap
A044820 Cosmax BTI	0.1x	n/a	US$57.70m

No more companies available in this PS range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A239610 is expensive based on its Price-To-Sales Ratio (3x) compared to the KR Personal Products industry average (0.9x).

Price to Sales Ratio vs Fair Ratio

What is A239610's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A239610 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A239610's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

NeoPharm

₩193.5b

Engages in the manufacturing and sale of skin care products in South Korea.

A092730

₩12,370.00

-3.7%

8.0%

NOVAREXLtd

₩136.0b

Manufactures, wholesales, and retails health and functional foods in South Korea and internationally.

A194700

₩7,680.00

-21.6%

-30.8%

Manyo Factory

₩277.1b

Produces and sells skin care products in South Korea.

A439090

₩16,920.00

-6.0%

-30.4%